CN1274362C - 一种预防和治疗艾滋病药物的制备方法 - Google Patents
一种预防和治疗艾滋病药物的制备方法 Download PDFInfo
- Publication number
- CN1274362C CN1274362C CNB021092516A CN02109251A CN1274362C CN 1274362 C CN1274362 C CN 1274362C CN B021092516 A CNB021092516 A CN B021092516A CN 02109251 A CN02109251 A CN 02109251A CN 1274362 C CN1274362 C CN 1274362C
- Authority
- CN
- China
- Prior art keywords
- medicine
- tsst
- toxin
- aids
- staphylococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title description 2
- 101000794214 Staphylococcus aureus Toxic shock syndrome toxin-1 Proteins 0.000 claims abstract description 20
- 239000003053 toxin Substances 0.000 claims abstract description 12
- 231100000765 toxin Toxicity 0.000 claims abstract description 12
- 229960000723 ampicillin Drugs 0.000 claims abstract description 9
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000012531 culture fluid Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000005277 cation exchange chromatography Methods 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000030961 allergic reaction Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 239000002775 capsule Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 7
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 6
- 230000036737 immune function Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031957 HIV carrier Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- -1 beta galactose glycosides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007750 drug combination effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000026498 progressive emaciation Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种预防和治疗艾滋病的药物，以金黄色葡萄球菌TSST-1毒素为预防和治疗艾滋病药物的活性组份，其中金黄色葡萄球菌TSST-1毒素分离于在含有氨苄青霉素的培养液中培养后的大肠埃希氏菌(Escherichia coli)XHT CGMCC No.0662菌体中。本发明克服了目前临床常用治疗方法存在的不足，能显著提高CD4/CD8的比值，疗效确切，药物毒副作用小，无过敏反应。
Description
技术领域
本发明涉及生物技术，具体地说是一种从培养的新菌株中获取用于预防和治疗艾滋病药物的制备方法。
背景技术
艾滋病由人类免疫缺陷病毒(HIV)感染而引起，导致被感染者免疫功能的部分或完全丧失，继而发生机会性感染、肿瘤等。HIV侵入人体后主要攻击的是一种带CD4的淋巴细胞(T4淋巴细胞)，这种细胞是免疫系统的基本组成部分，HIV通过大量、不断地复制与释放，导致T4淋巴细胞大量死亡，使人体内T4淋巴细胞明显减少，感染者免疫功能遭到严重破坏，造成免疫缺陷；临床表现为各种机会性感染与肿瘤。HIV一进入人体，这个人就成为HIV感染者，先是处于潜伏期，以后可逐渐发展成艾滋病病人；处于潜伏期的感染者免疫功能没有受到严重破坏，因而没有明显的临床症状。从HIV感染者到艾滋病病人这段时间的长短与感染者的年龄生活医疗条件、心理生理状况、感染病毒的类型等多种因素有关，短则几个月，长则20年以上；当感染者的免疫系统遭到一定程度的破坏(检查发现T4淋巴细胞计数显著下降，CD4/CD8淋巴细胞计数比值＜1等)，可出现一系列临床症状(如发生各种细菌、真菌、病毒感染及肿瘤)，就发展成艾滋病病人；人一旦受到HIV感染将终身携带病毒，因此HIV携带者和艾滋病病人都能传播病毒。
目前尚无可根治HIV感染的药物，也没有证据表明人体会对HIV产生保护性免疫，因此大多数病人会死于反复的继发感染及肿瘤；但早期治疗与预防可延缓病程的发展，提高生活质量；HIV感染者可定期检测T4淋巴细胞计数(正常值为500～1600/微升，T4/T8比值为(1.5～1.7)∶1)，当T4淋巴细胞计数≥200/微升时，可按免疫功能正常情况对感染者进行处理。目前临床上常用的治疗方法有以下三方面：(1)抗病毒治疗：如用叠氮胸苷(AZT)、双脱氧胞苷(DDC)等，目前国际上认为联合用药效果较好，但费用昂贵，一般发展中国家的感染者难以承受。(2)各种机会性感染和肿瘤的处理：由于HIV感染者免疫功能异常，发生感染时往往病情较重，难以控制，加上感染导致肝、肾功能不全，使用药物治疗时还要注意HIV感染者容易出现药物的毒副作用或过敏反应。(3)支持疗法：以提高机体免疫力为主要目的，同时要重视心理治疗和营养疗法。
发明内容
为了克服目前临床常用治疗方法存在的不足，本发明的目的在于提供一种新的大肠埃希氏菌菌株培养物；具有预防和治疗艾滋病功效；其疗效确切，毒副作用小。
为实现上述目的，本发明提供了一种预防和治疗艾滋病的药物是以金黄色葡萄球菌TSST-1毒素作为预防和治疗艾滋病药物的活性组份。
其中还可加入适量的药物辅料；经常采用的药物辅料为右旋糖苷、甘露醇；
所述金黄色葡萄球菌TSST-1毒素分离于大肠埃希氏菌(Escherichia coli)XHT CGMCC No.0662菌体中；
TSST-1毒素的具体制备过程为：首先以大肠埃希氏菌(Escherichia coli)XHT CGMCC No.0662于含有氨苄青霉素的培养液中培养，然后从菌体中分离出工程菌XHT表达的金黄色葡萄球菌TSST-1毒素；
所述分离过程为离心收集菌体，破碎菌体，离心去除菌体碎片，去除菌体碎片的提取液进行透析或超滤后，经阳离子层析柱纯化，用5～200mmol/L PB缓冲液线性梯度洗脱，收集合TSST-1峰的溶液；
所述培养液中氨苄青霉素的浓度为80～120μg/ml；
所述培养液为LB培养液，其PH为6.5～7.5；
本发明中所涉及的大肠埃希氏菌(Escherichia coli)已经于2001年12月10日保藏在中国微生物菌种保藏管理委员会普通微生物中心，保藏号为CGMCC No.0662；菌株代号为XHT。
菌株的情况：从金黄色葡萄球菌的DNA中获得TSST-1基因，以质粒PBV220为载体，以大肠杆菌DH5α为受体菌，自行构造表达TSST-1的工程菌。
菌株CGMCC No.0662的特征：
1.形态特征：为两端钝圆的中等大肠杆菌，宽约0.6μm，长约2～3μm，单独散在，不形成长链条，周围有菌毛。
2.培养特征：为需氧及兼性厌氧菌，在普通LB培养基上生长良好，最适PH7.2～7.4，最适培养增值温度为30℃，诱导表达温度为42℃；普通琼脂培养18～24小时，形成凸起，光滑、湿润，乳白色，边缘整齐的针尖到大头钉帽大小菌落；伊红美蓝琼脂上产生紫黑色带金属光泽的菌落；远滕琼脂上产生黄色菌落。
3.染色特征：革兰氏阴性染色。
4.生理生化特征：能分解葡萄糖、麦芽糖、甘露醇，产酸产气，β-半乳糖苷部分缺失，具有氨苄青霉素抗性，可表达金黄色葡萄球菌TSST-1毒素。
本发明的药物是：通过基因工程的方法，构造出表达金黄色葡萄球菌TSST-1毒素的工程菌种，并从中纯化出TSST-1毒素，制成药物制剂，用于预防和治疗艾兹病的药物。
本发明具有如下优点：克服了目前临床常用治疗方法存在的不足，能显著提高CD4/CD8的比值，疗效确切，毒副作用小，无过敏反应。
具体实施方式
实施例1
接种XHT工程菌于1ml含氨苄青霉素(100μg/ml)的LB培养液中，37℃摇床培养12小时后，转接到300ml含氨苄青霉素(100μg/ml)的LB培养液的三角瓶中，于恒温摇床30℃培养8小时(8～12小时即可)至对数生长期，按5％(按体积百分含量计)接种量，接种于发酵罐中，再于30℃培养12小时，升温至42℃，继续培养6小时(3～6小时均可)。
离心收集菌体，高压匀浆破碎菌体，离心去除菌体碎片，去除菌体碎片后的提取液进行透析，经透析后的样品，上阳离子层析柱(本实施例为羧甲基纤维素层析柱)纯化。依次用5mmol/L PB缓冲液(PH5.5)、30mmol/L PB缓冲液(PH6.0)、45mmol/L PB缓冲液(PH6.0)、200mmol/L PB缓冲液(PH6.8)分步洗脱，收集含TSST-1峰的溶液，经SDS-PAGE，免疫双扩、ELISA等方法进行测定，检测合格(纯度≥95％)后加入5％(按重量百分含量计)的右旋糖苷，喷雾干燥，制得喷雾干粉，分别制成胶囊或片剂。
(1)胶囊中加入适量淀粉，制得胶囊剂，每粒胶囊含TSST-110ng。
(2)片剂(1000片)，分别加入适量的淀粉26g，糊精42g及硬脂酸镁0.7g，TSST-1 10ng及丙烯酸树脂适量(约占总重量的3～5％)制得肠溶片。
实施例2
接种XHT工程菌于1ml含氨苄青霉素(100μg/ml)的LB培养液中，37℃摇床培养12小时后，转接到300ml含氨苄青霉素(100μg/ml)的LB培养液的三角瓶中，于恒温摇床30℃培养8小时至对数生长期，按5％接种量，接种于发酵罐中，再于30℃培养12小时，升温至42℃，继续培养6小时。
离心收集菌体，破碎菌体，离心去除菌体碎片，去除菌体碎片后的提取液在PH5.5的条件下透析，经透析后的样品，上阳离子层析柱纯化；依次用6mmol/L PB缓冲液(PH5.0)、8mmol/L PB缓冲液(PH6.6)、45mmol/L PB缓冲液(PH6.6)、100mmol/L PB缓冲液(PH6.8)分步洗脱，收集含TSST-1峰的溶液，经SDS-PAGE，免疫双扩、ELISA等方法进行测定，检测合格后加入5％的甘露醇，喷雾干燥，制得喷雾干粉，分别制成胶囊或片剂。
(1)胶囊中加入适量淀粉，制得胶囊剂，每粒胶囊含TSST-110ng。
(2)片剂(1000片)，分别加入适量的淀粉26g，糊精42g及硬脂酸镁0.7g，TSST-1 10ng及丙烯酸树脂适量制得肠溶片。
实验例
大多数爱滋病患者在发病阶段呈进行性消瘦，体重减轻，免疫功能下降，T淋巴细胞分布异常，CD4/CD8降低，10例患者服用本品(胶囊)一个月后，T细胞亚群检查的比较。
治疗前及治疗后T细胞亚群检查的比较(X±S)
| n | CD4 | CD8 | CD4/CD8 | |
| 治疗前 | 10 | 22.84±1.57 | 26.00±1.87 | 0.88±0.18 |
| 治疗后 | 10 | 25.19±5.41 | 23.32±5.15 | 1.08士0.22 |
Claims (5)
1.一种预防和治疗艾滋病药物的制备方法，其特征在于以金黄色葡萄球菌TSST-1毒素为预防和治疗艾滋病药物的活性组份；
所述金黄色葡萄球菌TSST-1毒素分离于大肠埃希氏菌Escherichia coli XHT CGMCC No.0662菌体中。
2.按照权利要求1所述的预防和治疗艾滋病药物的制备方法，其特征在于首先以大肠埃希氏菌Escherichia coli XHT CGMCCNo.0662于含有氨苄青霉素的培养液中培养，然后从菌体中分离出工程菌XHT表达的金黄色葡萄球菌TSST-1毒素。
3.按照权利要求2所述的预防和治疗艾滋病药物的制备方法，其特征在于所述培养液中氨苄青霉素的浓度为80～120μg/ml。
4.按照权利要求2所述的预防和治疗艾滋病药物的制备方法，其特征在于所述培养液为LB培养液，PH为6.5～7.5。
5.按照权利要求2所述预防和治疗艾滋病药物的制备方法，其特征在于所述分离过程为离心收集菌体，破碎菌体，离心去除菌体碎片，去除菌体碎片的提取液进行透析或超滤后，经阳离子层析柱纯化，用5～200mmol/L PB缓冲液线性梯度洗脱，收集含TSST-1峰的溶液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021092516A CN1274362C (zh) | 2002-03-06 | 2002-03-06 | 一种预防和治疗艾滋病药物的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021092516A CN1274362C (zh) | 2002-03-06 | 2002-03-06 | 一种预防和治疗艾滋病药物的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1442200A CN1442200A (zh) | 2003-09-17 |
| CN1274362C true CN1274362C (zh) | 2006-09-13 |
Family
ID=27793268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021092516A Expired - Lifetime CN1274362C (zh) | 2002-03-06 | 2002-03-06 | 一种预防和治疗艾滋病药物的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274362C (zh) |
-
2002
- 2002-03-06 CN CNB021092516A patent/CN1274362C/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1442200A (zh) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1311035A (zh) | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 | |
| CN111803533A (zh) | 降血糖、降血脂组合物、制备方法及其应用 | |
| US11766465B2 (en) | External composition for wound healing containing lactobacillus fermentation product and method for promoting wound healing using the same | |
| CN1274362C (zh) | 一种预防和治疗艾滋病药物的制备方法 | |
| JP3995733B2 (ja) | 免疫賦活組成物 | |
| CN100490829C (zh) | 治疗结肠炎、胃炎、胃癌的富硒猴头菌提取物制剂及其制备方法 | |
| CN106668100B (zh) | 八宝丹在制备治疗脑膜炎药物中的应用 | |
| US20020114794A1 (en) | Staphylococcus aureus culture and preparation thereof | |
| JPS58318B2 (ja) | 制癌性物質の製造方法 | |
| CN1245509C (zh) | 水蛭素突变体HV2－Lys47的生产方法及其专用表达载体与菌株 | |
| CA1286623C (en) | Liver function-improving agent and blood pressure- lowering agent | |
| CN114470007A (zh) | 含乳酸菌发酵产物之创伤外用组合物及其用途 | |
| CN1208731A (zh) | 重组人α型复合干扰素及其制备方法和用途 | |
| CN100355428C (zh) | 一种中草药凤尾草的制备工艺及用途 | |
| CN1090602A (zh) | 绿脓杆菌msha菌毛株及其建立 | |
| CN100344747C (zh) | 硫酸化nf1菌多糖——抗艾滋病药及其制备方法 | |
| CA1276897C (en) | Hypocholesterolemically active rna fractions | |
| JPH029600B2 (zh) | ||
| CN100388948C (zh) | 黄精凝集素ⅱ蛋白在制备治疗或预防艾滋病的药中的应用 | |
| FR2703252A1 (fr) | Complexe immunomodulateur anti SIDA. | |
| CN101921820A (zh) | 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用 | |
| Grehn | Endotoxins of gram-negative anaerobic bacteria | |
| CN101875688A (zh) | 重组肿瘤特异性凋亡因子制备方法中的叶酸化修饰步骤及其制品的应用 | |
| CN1101196C (zh) | 葡萄球菌菌苗注射液及制备方法 | |
| CN1222313C (zh) | 新型金葡菌素制剂及其制作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090306 Address after: Room 1209, incubator, Nanshan District hi tech Industrial Development Zone, Shenzhen, Guangdong Patentee after: Shenzhen associated gene engineering Co., Ltd. Address before: 19, 8, Miyoshi street, Heping District, Liaoning, Shenyang Patentee before: Xiehe Group Co., Ltd., Shenyang |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN CITY XIELIAN GENETIC ENGINEERING CO., LTD Free format text: FORMER OWNER: SHENYANG XIEHE GROUP CO.,LTD. Effective date: 20090306 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160412 Address after: Hi Tech road Shenyang city Liaoning province 110179 Hunnan New District No. 30 Patentee after: Xiehe Biological Pharmaceutical Co., Ltd., Shenyang Address before: 518057 incubator, room 1209, Nanshan District hi tech Industrial Development Zone, Shenzhen, Guangdong Patentee before: Shenzhen associated gene engineering Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170213 Address after: 313113 Zhejiang city of Huzhou province Changxing County Si'an Town Industrial Zone Patentee after: Changxin Biological Medicine Co Ltd Address before: Hi Tech road Shenyang city Liaoning province 110179 Hunnan New District No. 30 Patentee before: Xiehe Biological Pharmaceutical Co., Ltd., Shenyang |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20180508 Address after: 518057 A1, unit 303, Kexing Science Park, Keyuan Road, central Nanshan District, Shenzhen, Guangdong. Patentee after: Shenzhen new synergy Health Management Co., Ltd. Address before: 313113 Industrial Zone, Si an town, Changxing County, Huzhou, Zhejiang Patentee before: Changxin Biological Medicine Co Ltd |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060913 |
|
| CX01 | Expiry of patent term |